Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years
NCT ID: NCT00546988
Last Updated: 2007-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
600 participants
INTERVENTIONAL
2001-10-31
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard risk IFN
Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation
No interventions assigned to this group
Standard risk PEGIFN
Maintenance treatment with pegylated interferon following autologous stem cell transplantation
No interventions assigned to this group
High risk allo
Allogeneic stem cell transplantation from an HLA identical related or unrelated donor
allogeneic stem cell transplant
High risk auto
Second cycle of high-dose melphalan in subjects without an HLA-identical donor
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
allogeneic stem cell transplant
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Salmon-and-Durie stage II or III
* Less than or equal to 60 years
* Signed informed consent
Exclusion Criteria
* Unable to adhere to study protocol
* Pregnancy
* Not received subject's informed consent
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Wuerzburg
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hermann Einsele, M.D.
Role: PRINCIPAL_INVESTIGATOR
Wuerzburg University Hospital, Dept. of Hematology and Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medizinische Univ.-Klinik Graz
Graz, , Austria
Klin. Abt. für Onkologie, AKH Wien
Vienna, , Austria
Staedtisches Klinikum
Augsburg, , Germany
Dept. of Hematology/Oncology, Charité Berlin
Berlin, , Germany
Charité University Medicine
Berlin, , Germany
University Hospital
Erlangen, , Germany
Krankenhaus Nordwest
Frankfurt, , Germany
Freiburg University Hospital
Freiburg im Breisgau, , Germany
Georg August University Hospital
Göttingen, , Germany
Ernst-Moritz Arndt University Hospital
Greifswald, , Germany
Martin-Luther University Hospital
Halle, , Germany
University Hospital Eppendorf
Hamburg, , Germany
Hannover Medical School
Hanover, , Germany
Saarland University Hospital
Homburg/Saar, , Germany
Schleswig-Holstein University Hospital
Lübeck, , Germany
Mainz University Hospital
Mainz, , Germany
Dept. of Internal Medicine, Ludwig-Maximilian-University Munich
Munich, , Germany
Klinikum rechts der Isar
Munich, , Germany
Dept. of Internal Medicine A, University Muenster
Münster, , Germany
Nuremberg Central Hospital
Nuremberg, , Germany
Oldenburg Hospital
Oldenburg, , Germany
University Hospital
Regensburg, , Germany
Katharinenhospital
Stuttgart, , Germany
Diakonissenkrankenhaus
Stuttgart, , Germany
Tubingen University Hospital
Tübingen, , Germany
Dept. of Internal Medicine III, University of Ulm
Ulm, , Germany
Ulm University Hospital
Ulm, , Germany
Horst-Schmidt-Kliniken
Wiesbaden, , Germany
Dept. of Internal Medicine II, University of Wuerzburg
Würzburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Werner Linkesch, MD
Role: primary
Johannes Drach, MD
Role: primary
Orhan Sezer, MD
Role: primary
Orhan Sezer, M.D.
Role: primary
Monika Engelhardt, M.D.
Role: primary
Hans H Wolf, M.D.
Role: primary
Dietrich Peest, M.D.
Role: primary
Michael Pfreundschuh, M.D.
Role: primary
Christian Straka, MD
Role: primary
Martin Kropff, MD
Role: primary
Hannes Wandt, M.D.
Role: primary
Bernd, Metzner
Role: primary
Hans G Mergenthaler, M.D.
Role: primary
Katja Weisel, M.D.
Role: primary
Peter Liebisch, MD
Role: primary
Norbert Frickhofen, M.D.
Role: primary
Hermann Einsele, MD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Site of the German association of the leading research groups in lymphoid malignancies
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DSMM V
Identifier Type: -
Identifier Source: org_study_id